Læknablaðið - 15.04.2008, Blaðsíða 43

FRÆÐIGREINAR
LUNGNAKRABBAMEIN
85. Laroche C, Wells F, Coulden R, et al. Improving surgical
resection rate in lung cancer. Thorax 1998; 53:445-9.
86. Kim ES, Bosquee L. The importance of accurate lymph
node staging in early and locally advanced non-small cell
lung cancer: an update on available techniques. J Thorac
Oncol 2007; 2 Suppl 2: S59-67.
87. Whitson BA, Groth SS, Maddaus MA. Surgical assessment
and intraoperative management of mediastinal lymph
nodes in non-small cell lung cancer. Ann Thorac Surg 2007;
84:1059-65.
88. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy
versus limited resection for T1 N0 non-small cell lung
cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;
60: 615-22; discussion 622-3.
89. Guðbjartsson T, Gyllsted E, Pikwer A, Jonsson P. Early
Surgical Results Following Pneumonectomy for Non-Small
Cell Lungcancer are not Affected by Preoperative Radio-
and Chemotherapy. Ann Thorac Surg (in press) 2007.
90. Myrdal G. Lung cancer. Epidemiological and clinical
studies with special reference to surgical treatment
(Dissertation). Uppsala: Uppsala University; 2003.
91. Deslauriers J, Gregoire J, Jacques LF, Piraux M, Guojin L,
Lacasse Y. Sleeve lobectomy versus pneumonectomy for
lung cancer: a comparative analysis of survival and sites or
recurrences. Ann Thorac Surg 2004; 77: 1152-6; discussion
1156.
92. McKenna RJ, Jr. Surgical management of primary lung
cancer. Semin Oncol 2007; 34: 250-5.
93. McKenna RJ, Jr., Mahtabifard A, Pickens A, Kusuanco D,
Fuller CB. Fast-tracking after video-assisted thoracoscopic
surgery lobectomy, segmentectomy, and pneumonectomy.
Ann Thorac Surg 2007; 84:1663-7; discussion 1667-8.
94. West D, Rashid S, Dunning J. Does video-assisted thora-
coscopic lobectomy produce equal cancer clearance
compared to open lobectomy for non-small cell carcinoma
of the lung? Interact Cardiovasc Thorac Surg 2007; 6:110-6.
95. Shen KR, Meyers BF, Lamer JM, Jones DR. Special
treatment issues in lung cancer: ACCP evidence-based
clinical practice guidelines (2nd edition). Chest 2007; 132(3
Suppl); 290S-305S.
96. Chapelier A, Fadel E, Macchiarini P, et al. Factors affecting
long-term survival after en-bloc resection of lung cancer
invading the chest wall. Eur J Cardiothorac Surg 2000;
18(5): 513-8.
97. Downey RJ, Martini N, Rusch VW, Bains MS, Korst RJ,
Ginsberg RJ. Extent of chest wall invasion and survival in
patients with lung cancer. Ann Thorac Surg 1999; 68: 188-
93.
98. Robinson LA, Ruckdeschel JC, Wagner H, Jr., Stevens CW.
Treatment of non-small cell lung cancer-stage IIIA: ACCP
evidence-based clinical practice guidelines (2nd edition).
Chest 2007; 132(3 Suppl): 243S-265S.
99. Socinski MA, Crowell R, Hensing TE, et al. Treatment of
non-small cell lung cancer, stage IV: ACCP evidence-based
clinical practice guidelines (2nd edition). Chest 2007; 132(3
Suppl):277S-289S.
100. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative
chemotherapy followed by surgery compared with
primary surgery in resectable stage I (except T1N0), II, and
Illa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-
53.
101. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-
up of patients enrolled in a randomized trial comparing
perioperative chemotherapy and surgery with surgery
alone in resectable stage IIIA non-small-cell lung cancer.
Lung Cancer 1998; 21:1-6.
102. Schuchert MJ, Luketich JD. Solitary sites of metastatic
disease in non-small cell lung cancer. Curr Treat Options
Oncol 2003; 4: 65-79.
103. Asamura H, Ginsberg RJ. Treatment of smal cell lung
cancer: Surgery. London: Martin Dunitz; 2000.
104. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II
non-small cell lung cancer in patients not sufficiently fit for
or declining surgery (medically inoperable): a systematic
review. Thorax 2001; 56: 628-38.
105. Sirzen F, Kjellen E, Sorenson S, Cavallin-Stahl E. A
systematic overview of radiation therapy effects in non-
small cell lung cancer. Acta Oncol 2003; 42: 493-515.
106. Emami B, Mirkovic N, Scott C, et al. The impact of regional
nodal radiotherapy (dose/volume) on regional progression
and survival in unresectable non-small cell lung cancer: an
analysis of RTOG data. Lung Cancer 2003; 41: 207-14.
107. Komaki R, Sause WT, Byhardt RW, et al. Non-small cell
lung cancer, nonsurgical, aggressive therapy. American
College of Radiology. ACR Appropriateness Criteria.
Radiology 2000; 215 Suppl: 1319-30.
108. Gravolin M, Rowell K, de Groot J. Interventions to support
the decision-making process for older people facing
the possibility of long-term residential care. Cochrane
Database Syst Rev 2007(3): CD005213.
109. Postoperative radiotherapy for non-small cell lung cancer.
PORT Meta-analysis Trialists Group. Cochrane Database
Syst Rev 2000(2): CD002142.
110. Bogart JA, Aronowitz JN. Localized non-small cell lung
cancer: adjuvant radiotherapy in the era of effective
systemic therapy. Clin Cancer Res 2005; 11(13 Pt 2): 5004s-
5010s.
111. Stupp R, Monnerat C, Turrisi AT, 3rd, Perry MC, Leyvraz
S. Small cell lung cancer: state of the art and future
perspectives. Lung Cancer 2004; 45:105-17.
112. Janne PA, Freidlin B, Saxman S, et al. Twenty-five years of
clinical research for patients with limited-stage small cell
lung carcinoma in North America. Cancer 2002; 95: 1528-
38.
113. Samson DJ, Seidenfeld J, Simon GR, et al. Evidence for
management of small cell lung cancer: ACCP evidence-
based clinical practice guidelines (2nd edition). Chest 2007;
132(3 Suppl): 314S-323S.
114. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty
years of phase III trials for patients with extensive-stage
small-cell lung cancer: perceptible progress. J Clin Oncol
1999; 17:1794-801.
115. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in
completely resected non-small-cell lung cancer. J Clin
Oncol 2005; 23: 3270-8.
116. Douillard JY, Rosell R, De Lena M, et al. Adjuvant
vinorelbine plus cisplatin versus observation in patients
with completely resected stage IB-IIIA non-small-cell
lung cancer (Adjuvant Navelbine Intemational Trialist
Association [ANITA]): a randomised controlled trial.
Lancet Oncol 2006; 7: 719-27.
117. Pignin J, Tibodet H, Scagliotti G, et al. Lung adjuvant
cisplatin evaluation (LACE): A pooled analysis of five
randomized clinical trials including 4584 patients. J Clin
Oncol 2006(June 20): 7008.
118. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus
cisplatin vs. observation in resected non-small-cell lung
cancer. N Engl J Med 2005; 352:2589-97.
119. Farray D, Mirkovic N, Albain KS. Multimodality therapy
for stage III non-small-cell lung cancer. J Clin Oncol 2005;
23: 3257-69.
120. Jett JR, Schild SE, Keith RL, Kesler KA. Treatment of non-
small cell lung cancer, stage IIIB: ACCP evidence-based
clinical practice guidelines (2nd edition). Chest 2007; 132(3
Suppl): 266S-276S.
121. Wakelee H, Belani CP. Optimizing first-line treatment
options for patients with advanced NSCLC. Oncologist
2005; 10 Suppl 3:1-10.
122. Sandler A. Bevacizumab in non small cell lung cancer. Clin
Cancer Res 2007; 13(15 Pt 2): s4613-6.
123. Hanna N, Shepherd FA, Fossella FV, et al. Randomized
phase III trial of pemetrexed versus docetaxel in patients
with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol 2004; 22:1589-97.
124. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in
previously treated non-small-cell lung cancer. N Engl J Med
2005; 353:123-32.
125. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al.
Combination of EGFR gene copy number and protein
expression predicts outcome for advanced non-small-cell
lung cancer patients treated with gefitinib. Ann Oncol 2007;
18: 752-60.
LÆKNAblaðið 2008/94 31 1